Tiziana Life Sciences (TLSA) Non-Current Assets (2017 - 2025)
Tiziana Life Sciences (TLSA) posted Non-Current Assets of $2.9 million for Q4 2025, up 16250.0% on a QoQ basis from $18000.0 in Q2 2025, and up 18293.75% year-over-year from N/an in Q4 2024.
Analysis
Tiziana Life Sciences (TLSA) Non-Current Assets (2017 - 2025) Analysis & Trends
Tiziana Life Sciences has reported Non-Current Assets for 9 years, with the latest figure at $2.9 million in Q4 2025.
- On a quarterly basis, Non-Current Assets rose 18293.75% year-over-year to $2.9 million in Q4 2025; TTM through Dec 2025 was $12.2 million, a 76287.5% increase from a year earlier, with the FY2025 full-year figure at $2.9 million, up 18293.75% from the prior year.
- Non-Current Assets was $2.9 million for Q4 2025 at Tiziana Life Sciences, up from $18000.0 in the prior quarter.
- The five-year high for Non-Current Assets was $4.8 million in Q4 2023, with the low at $16000.0 in Q2 2024.
- Average Non-Current Assets over 5 years is $1.6 million, with a median of $1.5 million recorded in 2021.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets tumbled 99.67% in 2024, then surged 18293.75% in 2025.
- Over 5 years, Non-Current Assets stood at $147000.0 in 2021, then jumped by 1393.2% to $2.2 million in 2022, then jumped by 120.82% to $4.8 million in 2023, then sank by 99.67% to $16000.0 in 2024, then soared by 18293.75% to $2.9 million in 2025.
- The last three Non-Current Assets figures came in at $2.9 million (Q4 2025), $18000.0 (Q2 2025), and $16000.0 (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 60.68 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 35.42 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 14.88 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 23.28 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.96 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 5.15 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 24.78 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 564.41 Mn |
| 10 | Tiziana Life Sciences | 113.92 Mn | 113.92 Mn | - | 2.94 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 2.94 Mn |
| Jun 30, 2025 | 18,000.00 |
| Dec 31, 2024 | 16,000.00 |
| Jun 30, 2024 | 16,000.00 |
| Dec 31, 2023 | 4.85 Mn |
| Jun 30, 2023 | 2.24 Mn |
| Dec 31, 2022 | 2.20 Mn |
| Jun 30, 2022 | 2.81 Mn |
| Dec 31, 2021 | 147,000.00 |
| Jun 30, 2021 | 715,000.00 |
| Dec 31, 2020 | 480,000.00 |
| Jun 30, 2020 | 951,138.83 |
| Dec 31, 2019 | 853,721.34 |
| Jun 30, 2019 | 746,061.32 |
| Dec 31, 2018 | 286,949.09 |
| Jun 30, 2018 | 311,979.26 |
| Dec 31, 2017 | 23,897.97 |